SCHEMBL4568620

SCHEMBL4568620

COc1ccc(C2(c3ccc(OC)cc3)C=Cc3c4c(c5cc(CO)c(OC)cc5c3O2)-c2ccccc2C4(C)C)cc1

nearest known ligand 0.32

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PDCD1 Q15116 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
EDNRA P25101 2/20 0.31
EDNRB P24530 1/20 0.31
HTT P42858 1/20 0.31
GPR84 Q9NQS5 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10102299 0.97 PDCD1 (0.32) PDCD1CD274
SCHEMBL9928121 0.95 HTT (0.32) HTTGPR84
SCHEMBL4568636 0.92
SCHEMBL29664129 0.91 PGR (0.32) HTT
SCHEMBL1009516 0.91 PGR (0.32) HTT
SCHEMBL10262650 0.91 EDNRA (0.35) EDNRAEDNRB
SCHEMBL15763098 0.90 PDCD1 (0.31) PDCD1CD274
SCHEMBL1046559 0.89 MEN1 (0.32) HTT
SCHEMBL29453311 0.89 MEN1 (0.32) HTT
SCHEMBL4568712 0.89

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9588257-B2 Photochromic curable composition TOKUYAMA CORPORATION (JP) 2017-03-07 US disclosed
US-20160116765-A1 PHOTOCHROMIC CURABLE COMPOSITION TOKUYAMA CORPORATION (JP) 2016-04-28 US disclosed
US-20150368552-A1 PHOTOCHROMIC CURABLE COMPOSITION TOKUYAMA CORPORATION (JP) 2015-12-24 US disclosed
US-20150030866-A1 PHOTOCHROMIC CURABLE COMPOSITION TOKUYAMA CORPORATION (JP) 2015-01-29 US disclosed
US-20140203226-A1 (METH)ACRYLATE COMPOUND AND PHOTOCHROMIC CURABLE COMPOSITION CONTAINING THE (METH)ACRYLATE COMPOUND TOKUYAMA CORPORATION (JP) 2014-07-24 US disclosed
US-8778236-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2014-07-15 US disclosed
US-20140146285-A1 PHOTOCHROMIC CURABLE COMPOSITION TOKUYAMA CORPORATION (JP) 2014-05-29 US disclosed
US-8709308-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2014-04-29 US disclosed
US-8691120-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2014-04-08 US disclosed
US-20140054520-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2014-02-27 US disclosed
US-20140034884-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2014-02-06 US disclosed
US-8308995-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
US-8308996-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-11-13 US disclosed
US-20120170098-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2012-07-05 US disclosed
US-20120138876-A1 CHROMENE COMPOUND KASAI SOKO (JP) 2012-06-07 US disclosed
US-20120121934-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2012-05-17 US disclosed
US-8147726-B2 Chromene compound TOKUYAMA CORPORATION (JP) 2012-04-03 US disclosed
US-20110062396-A1 CHROMENE COMPOUND TOKUYAMA CORPORATION (JP) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140203226-A1 (METH)ACRYLATE COMPOUND AND PHOTOCHROMIC CURABLE COMPOSITION CONTAINING THE (METH)ACRYLATE COMPOUND TET1, MGMT, CRYAA PDCD1 4267/4885CD274 3980/4885EDNRA 1015/4885
US-20150368552-A1 PHOTOCHROMIC CURABLE COMPOSITION H1-0, CDH1, COL1A1 PDCD1 3657/4885CD274 2423/4885EDNRA 2926/4885
US-20120138876-A1 CHROMENE COMPOUND CHRM1, CBX8, CBX7 PDCD1 535/4885CD274 446/4885EDNRA 570/4885
US-20120170098-A1 CHROMENE COMPOUND CRY2, CRY1, SUN2 PDCD1 599/4885CD274 920/4885EDNRA 2966/4885
US-20110062396-A1 CHROMENE COMPOUND CDYL, NR0B1, NR1H2 PDCD1 2577/4885CD274 2040/4885EDNRA 1011/4885
US-20150030866-A1 PHOTOCHROMIC CURABLE COMPOSITION CRYAA, AHCY, WDR1 PDCD1 4796/4885CD274 4600/4885EDNRA 2395/4885
US-20120121934-A1 CHROMENE COMPOUND TST, CNOT1, CNOT9 PDCD1 2805/4885CD274 2561/4885EDNRA 4337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.